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Cardiopulmonary bypass (CPB) is a proinflammatory
state1 that is associated with enhanced myocardial tumor
necrosis factor–a (TNF) production. TNF is known to up-
regulate its own production, as well as the production of other
inflammatory and anti-inflammatory cytokines.2 In this
regard, interleukin-11 (IL-11) is a recently discovered multi-
functional cytokine that belongs to the gp130 receptor sub-
unit-linked family of anti-inflammatory cytokines.3 IL-11, a
powerful stimulant of hematopoiesis, is clinically used to
stimulate platelet production in patients with thrombocytope-
nia and is elevated in patients with disseminated intravascu-
lar coagulation.4 However, IL-11 also possesses potent anti-
inflammatory cytokine activity. Indeed, IL-11 decreases
murine serum TNF5 and lung TNF production in response to
endotoxin.6 Although our understanding of CPB–induced
proinflammatory cytokine production is accelerating,1,2 little
information exists regarding anti-inflammatory cytokine
release, which may lead to late immunologic vulnerability.7 It
remains unknown whether CPB induces the release of IL-11
and, if so, whether this correlates with the time course of late
leukocyte disability. Enhanced understanding of the kinetics
of IL-11 production after CPB may have important implica-
tions regarding the regulation of hematopoiesis, early inflam-
mation, and late immunosuppression.
Methods. Patients, 18 to 65 years of age, scheduled for
elective cardiac surgery but without other pre-existing disease
were considered eligible for the study. The 6 patients enrolled
underwent coronary artery bypass grafting at the University
Hospital or Veterans Administration Medical Center on the
University of Colorado Health Sciences Center Campus.
Standard extracorporeal circulation was performed with a
conventional membrane oxygenator, heat exchanger, and
centrifugal pump with the patient under moderate hypother-
mia (systemic temperature between 28°C and 30°C).
Myocardial protection was afforded with cold blood cardio-
plegic solution (4°C). The protocol to obtain serial blood
samples was approved by the University of Colorado Health
Sciences Center Combined Affiliated Institutional Review
Board, and written informed consent was obtained from all
patients before enrollment. The first blood sample (baseline)
was drawn during the patient’s preoperative anesthesia
appointment or, if the patient was in the hospital, the day
before the operation. Samples were collected at the onset of
CPB during the operation (time 0), and then 3, 6, 12, 24, and
36 hours after CPB. Further samples were also obtained 2 and
3 days after CPB. At each time point, 15 mL of venous blood
was collected into a heparinized syringe (10 units of heparin
per milliliter of blood). The heparinized blood samples were
centrifuged at 200g for 15 minutes and the plasma was
removed and stored at –70°C until assay. A 50-mL portion of
each plasma sample was used in triplicate for the IL-11 assay,
which was performed according to the manufacturer’s
instructions. In brief, the IL-11 assay uses the quantitative
sandwich enzyme immunoassay technique. Standards and
samples are loaded into the pre-coated wells (coated with
monoclonal antibodies specific for IL-11) of a 96-well
microtiter plate. Any IL-11 present in the plasma samples is
bound by the monoclonal antibody bound to the well. After
unbound sample is washed away, an enzyme-linked antibody
specific for IL-11 is added to the wells. After another wash to
remove unbound antibody, a color reagent is added that
directly reflects the quantity of bound enzyme-linked
anti–IL-11. The quantity is then read spectrophotometrically
and is expressed as picograms per milliliter of a known stan-
dard. Standard reagents were obtained from Sigma Chemical
Co, St Louis, Missouri, with the exception of the reagents for
the IL-11 assay, which were obtained from R&D Systems,
Minneapolis, Minnesota. Data are reported as the mean ±
standard error of the mean for all groups tested. Analysis of
variance was done with post hoc analysis using Bonferroni-
Dunn.
Results. The demographics, CPB time, number of coro-
nary artery bypasses performed, and length of stay for the
study patients are reported in Table I. A delayed sternal
wound infection developed in 1 patient, necessitating a sec-
ond hospital admission, wound debridement, and muscle flap
closure. The remaining 5 patients had uneventful hospital
courses and required no further hospitalizations related to
their operation. The kinetics of IL-11 release after CPB are
shown in Fig 1. IL-11 was undetectable in plasma obtained 0,
3, 6, and 12 hours after CPB. Twenty-four and 36 hours after
CPB, IL-11 was detectable in plasma from some of the
patients and undetectable in others, which yielded mean IL-
11 values of 2.8 ± 1.8 and 1.9 ± 1.2 pg/mL, respectively. At
48 hours, IL-11 was detectable in all patients, which resulted
in a significant increase in mean IL-11 levels to 7.6 ± 1.9
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pg/mL. Seventy-two hours after CPB, IL-11 levels had
declined.
Discussion. The results of this study constitute the initial
demonstration that CPB induces IL-11 production, which
peaks at 48 hours. This peak in IL-11 production is tempo-
rally correlated with late post-CPB neutrophil disability.7
CPB is a routine part of cardiac surgery, and the vast major-
ity of patients undergoing CPB recover uneventfully. In a
small number of patients the “postperfusion syndrome”
develops. This is characterized by diffuse inflammation,
increased capillary permeability, extravasation of plasma,
increased interstitial fluid, leukocytosis, fever, peripheral
vasoconstriction, and a diffuse bleeding diathesis in its most
severe form. Postperfusion syndrome is an exaggerated form
of the systemic inflammatory response syndrome, recog-
nized as an exuberant neutrophil/macrophage-mediated
response. Recent studies have implicated myocardial TNF
production and other proinflammatory cytokine production
in the pathogenesis of this syndrome.1 Proinflammatory
cytokines induce the later release of anti-inflammatory medi-
ators, apparently intended to neutralize the inflammatory
process in a negative feedback fashion. In its most severe
form, excessive anti-inflammatory cytokine release can
increase susceptibility to sepsis.1 IL-11 is a recently discov-
ered pluripotent anti-inflammatory cytokine whose biologic
impact is only beginning to be elucidated. IL-11 is a bone
marrow fibroblast-derived cytokine. IL-11 has a variety of in
vitro biologic activities within the hematopoietic, lym-
phopoietic, hepatic, adipose, bone, gut, and neuronal sys-
tems. Because of the overlapping biologic activities of IL-11
and cytokines such as IL-6, leukemic inhibitory factor, cil-
iary neutrophilic factor, and oncostatin-M, it is not surpris-
ing to find that these cytokines share a common signal trans-
ducer, the gp130 common receptor subunit. Through the
gp130 subunit, these cytokines disrupt the intracellular sig-
naling of proinflammatory cytokines. Indeed, several inves-
tigators have demonstrated beneficial effects of IL-11 in
experimental sepsis.6 Pretreatment with IL-11 significantly
reduces mortality in a murine model of toxic shock syn-
drome, a rat model of experimental group B streptococcal
sepsis, and a murine model of lethal endotoxemia.6 The anti-
inflammatory effects of IL-11 on both murine and rabbit
models of endotoxemia appear to be due to the inhibition of
the production of proinflammatory mediators. Trepicchio
and coworkers5 demonstrated that IL-11 in a dose-dependent
fashion reduced serum levels of pro-inflammatory mediators
such as TNF, IL-1– b , and interferon-g after endotoxin admin-
istration in mice. These pretreatment strategies appear to
inhibit injury-induced inflammation before its initiation.
However, when released as a result of injury and proinflam-
matory cytokine release, IL-11 appears to be associated with
late neutrophil disability. IL-11 production is temporally cor-
related with late post-CPB neutrophil disability.7 Given the
role of IL-11 in platelet formation, early regulation of inflam-
mation, and late immunosuppression, it appears as though reg-
ulating IL-11 production may be of future interest to cardio-
thoracic surgical investigation.
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Fig 1. Kinetics of IL-11 release after CPB. Before CPB, IL-
11 was undetectable in the plasma of the 6 patients examined.
After CPB, IL-11 was undetectable in plasma obtained at 3,
6, and 12 hours. However, 24 and 36 hours after CPB, IL-11
was detectable in plasma from some of the patients (2 of 6
patients at each time point; for 24 hours, P = .07; for 36
hours, P =.2). At 48 hours after CPB, IL-11 was detectable in
all patients, which resulted in a significant increase in mean
IL-11 levels (for 48 hours, P = .0001). At 72 hours after CPB,
IL-11 levels declined (for 72 hours, P = .05). 
Table I. Clinical characteristics of patients undergoing
CPB (n = 6; means ± standard deviation)
Mean age (y) 50.0 ± 5.7
Male 6 (100%)
CPB time (min) 107 ± 37.7
Crossclamp time (min) 68 ± 17.6
No. of CABGs 3.0 ± 1.1
Length of hospital stay (days) 4.8 ± 0.9
CPB, Cardiopulmonary bypass; CABG, coronary artery bypass graft.
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